Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer
<b>Background:</b> Adherence to oral anticancer therapies among breast cancer patients is an often-overlooked issue. A lack of patient compliance can be caused by several factors, and may hinder the efficacy of prescribed medication, leading to a shorter than expected survival. In this c...
Saved in:
| Main Authors: | Maria Rosaria Valerio, Federica Martorana, Maria Vita Sanò, Daniela Sambataro, Gianmarco Motta, Lucia Motta, Giuliana Pavone, Vittorio Gebbia, Giuseppa Scandurra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/3/546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
by: Judy King, et al.
Published: (2025-07-01) -
Grade III rash induced by abemaciclib in a patient with HR+/HER-2 negative breast cancer
by: Yu Yao, et al.
Published: (2025-05-01) -
Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
by: Anwar Al Nouri, et al.
Published: (2025-06-01) -
Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review
by: Maria Rosaria Valerio, et al.
Published: (2025-03-01) -
Case Report: Abemaciclib‐Induced Chronic Renal Failure
by: Lu Lin, et al.
Published: (2025-06-01)